 |
VasoMedical to Showcase EECP® Therapy at Africa Health Exhibition and Congress 2013 in Johannesburg, South Africa |
April 30, 2013 - WESTBURY, N.Y. - VasoMedical, Inc. (“VasoMedical”) (OTC BB: VASO), a diversified medical technology company specializing in the design, manufacture and sale of medical devices for noninvasive cardiology, including EECP® Therapy systems, the gold standard of ECP therapy, announced today that the Company will attend and exhibit at Africa Health Exhibition and Congress 2013 from May 7 – May 9, 2013 in Johannesburg, South Africa.
The Africa Health Exhibition and Congress is an international healthcare exhibition that allows companies to showcase hospital equipment, medical devices and pharmaceuticals to the growing Sub-Saharan healthcare market. The international event attracts more than 400 exhibitors and, this year, expects 5,000 visitors and delegates from 51 countries across the globe to attend.
At this event, VasoMedical will display and demonstrate its core technology, EECP® therapy, and its BIOX ambulatory monitoring products as well as its EZ patient management products.
“The Africa Health Exhibition is an important event for VasoMedical, as it allows us to communicate with medical professionals from across the globe and further expand our global reach to the growing markets in Africa,” said Larry Liebman, vice president, sales & marketing for VasoMedical. “As the Sub-Saharan Africa healthcare market is poised to reach $35 billion by 2016, we view this event as well timed to spread awareness about the Company's offerings.”
Mr. Liebman continued, “Our goal is to generate buzz around our core technology, EECP® Therapy, as a safe and effective non-invasive treatment for patients suffering from heart diseases such as angina and heart failure. If more physicians in the Sub-Saharan region to turn to EECP® Therapy as a go-to treatment option, it will enhance the lives of hundreds of thousands of patients suffering from cardiovascular disease, without the costs and risks of conventional invasive treatments.”
VasoMedical will be located at Booth 3E21 at the Gallagher Convention Center in Midrand.
About VasoMedical
VasoMedical, Inc. is a diversified medical technology company specializing in the manufacture and sale of medical devices and in the domestic sale of diagnostic imaging products. The Company's main proprietary products are EECP® Therapy systems, the gold standard of ECP treatment. The Company operates through three wholly owned subsidiaries: VasoSolutions, VasoMedical Global and VasoHealthcare. VasoSolutions manages and coordinates the design, manufacture and sales of EECP® Therapy systems, and other medical equipment operations; VasoMedical Global operates the Company's China-based subsidiaries; and VasoHealthcare is the operating subsidiary for the exclusive sales representation of GE Healthcare diagnostic imaging products in certain market segments. Additional information is available on the Company's website at www.vasomedical.com
About BIOX Instruments
BIOX Instruments Co., Ltd., a wholly owned subsidiary of VasoMedical, is based in Wuxi, Jiangsu Province, China. With long established expertise in miniaturization and low power consumption medical devices, it is a leading company in ambulatory monitoring systems consisting of ECG Holter recorders, ambulatory blood pressure monitoring (ABPM) systems as well as related analysis and reporting software. BIOX is in full compliance of revered quality and manufacturing standards such as ISO 13485, ISO 9001, US FDA cGMP as well as the Medical Device Directive of the European Union. BIOX products are FDA Cleared, CE Marked and Health Canada Listed. Furthermore, BIOX continues to provide OEM and OED services to many businesses that require effective solutions to product design and performance. Additional information is available on the Company's website at http://www.biox.com.cn.
Except for historical information contained in this release, the matters discussed are forward-looking statements that involve risks and uncertainties. When used in this release, words such as “anticipates”, “believes”, “could”, “estimates”, “expects”, “may”, “plans”, “potential” and “intends” and similar expressions, as they relate to the Company or its management, identify forward-looking statements. Such forward-looking statements are based on the beliefs of the Company's management, as well as assumptions made by and information currently available to the Company's management. Among the factors that could cause actual results to differ materially are the following: the effect of business and economic conditions; the effect of the dramatic changes taking place in the healthcare environment; the impact of competitive procedures and products and their pricing; medical insurance reimbursement policies; unexpected manufacturing or supplier problems; unforeseen difficulties and delays in the conduct of clinical trials and other product development programs; the actions of regulatory authorities and third-party payers in the United States and overseas; uncertainties about the acceptance of a novel therapeutic modality by the medical community; continuation of the GEHC agreement; and the risk factors reported from time to time in the Company's SEC reports. The Company undertakes no obligation to update forward-looking statements as a result of future events or developments.
Investor Contacts:
Todd Fromer / Garth Russell
KCSA Strategic Communications
212-896-1215 / 212-896-1250
tfromer@kcsa.com / grussell@kcsa.com
Media Contacts:
Lewis Goldberg / Samantha Wolf
KCSA Strategic Communications
212-896-1216 / 212-896-1220
lgoldberg@kcsa.com / swolf@kcsa.com